Overview

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis.
Phase:
N/A
Details
Lead Sponsor:
University of Virginia
Collaborators:
Merck Sharp & Dohme Corp.
National Institutes of Health (NIH)
Treatments:
Hormones